Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which includes 1,218,750 ordinary shares from the full exercise of the underwriters’ over-allotment option to purchase additional ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the symbol “GMDA.”

Based in Jerusalem, Israel, Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.

The Davis Polk corporate team included partner Derek Dostal and associates Gil Savir and Yushen Liu. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post